Monitoring System for Pregnancy Complications
(MOMS Trial)
Trial Summary
What is the purpose of this trial?
Pregnancy-related death is a growing public health issues, which are of particular concern to minority groups, including African-Americans and Spanish-speaking Latinas. Our proposal aims to improve a patient's ability to detect warning signs of pregnancy related death and seek medical care.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment Maternal Outcome Monitoring and Support system, Pregnancy Care Monitoring System, Maternal Health Support System?
Research suggests that early warning systems in obstetric care can help reduce maternal risks by alerting healthcare providers to potential complications early on. These systems, when implemented effectively, improve coordination among medical staff and support decision-making, which can lead to better maternal safety and outcomes.12345
Is the Monitoring System for Pregnancy Complications safe for humans?
The research highlights the importance of monitoring adverse events (unwanted effects) in pregnancy trials to ensure safety, but it does not provide specific safety data for the Monitoring System for Pregnancy Complications. It emphasizes the need for better safety monitoring and reporting systems to understand risks in pregnant women.26789
How is the Maternal Outcome Monitoring and Support system different from other treatments for pregnancy complications?
The Maternal Outcome Monitoring and Support system is unique because it focuses on continuous monitoring and early detection of pregnancy complications, which can help prevent severe outcomes by providing timely interventions. Unlike traditional treatments that may address complications after they occur, this system aims to proactively manage maternal health through real-time data and support.210111213
Research Team
Eligibility Criteria
This trial is for pregnant individuals over 28 weeks, identifying as Black/African American or Hispanic/Latino. Participants must be able to read and speak English or Spanish respectively, plan to deliver at specified NewYork-Presbyterian hospitals, be 18+, and receive healthcare in the U.S. Those with severe cognitive issues, major psychiatric illness, or terminal illnesses cannot join.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Participants receive the MOMS symptom monitoring and decision support intervention
Follow-up
Participants are monitored for safety and effectiveness after intervention
Treatment Details
Interventions
- Maternal Outcome Monitoring and Support system (Behavioural Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Columbia University
Lead Sponsor
Dr. Katrina Armstrong
Columbia University
Chief Executive Officer
MD from Johns Hopkins University, MS in Epidemiology from Harvard School of Public Health
Dr. Katrina Armstrong
Columbia University
Chief Medical Officer
MD from Harvard Medical School
National Institute on Minority Health and Health Disparities (NIMHD)
Collaborator
Dr. Eliseo J. Pérez-Stable
National Institute on Minority Health and Health Disparities (NIMHD)
Chief Executive Officer since 2015
MD from University of Miami
Dr. Rada Dagher
National Institute on Minority Health and Health Disparities (NIMHD)
Chief Medical Officer since 2024
MD from University of California, San Francisco